Deborah J. Vestal

Dr. Deborah J. Vestal

orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2011 in Journal of Interferon & Cytokine Research
Verified
Journal Article
Closed access
Deborah J. VestalDeborah J. Vestal
Deborah J. Vestal
JJJonathan A. Jeyaratnam
Jonathan A. Jeyaratnam
Originally identified by their unusual ability to bind guanosine monophosphate (GMP) nucleotide agarose, the guanylate-binding proteins (GBPs) were used extensively to promote our understanding of interferon-induced gene transcription and as markers of interferon responsiveness. Structural and biochemical analyses of human GBP-1 subsequently demonstrated that the GBPs are a unique subfamily of guanosine triphosphatase (GTPases) that hydrolyze guanosine triphosphate (GTP) to both guanosine diphosphate (GDP) and GMP. As members of the larger dynamin superfamily of GTPases, GBPs exhibit such properties as nucleotide-dependent oligomerization and concentration-dependent GTPase activity. Recently, progress has been made in assigning functions to members of the GBP family. While many of these functions involve protection against intracellular pathogens, a growing number of them are not directly related to pathogen protection. It is currently unclear how the unusual properties of GBPs contribute to this growing list of functions. As future studies uncover the molecular mechanism(s) of action of the GBPs, we will gain a greater understanding of how individual GBPs can mediate what currently appears to be a divergent set of functions.

1 August 2005 in Journal of Interferon & Cytokine Research
Verified
Journal Article
Closed access
Deborah J. VestalDeborah J. Vestal
Deborah J. Vestal
The guanylate-binding proteins (GBPs) were first identified in the late 1970s, and within a short period of time, investigators were aware that GBPs possessed unique properties, in particular the ability to bind GMP agarose. Since then, much study has gone into understanding their mechanism of induction by interferons (IFNs) and other cytokines, and they have been used extensively as markers for IFN responsiveness in both cells and organisms. In time, we learned that GBPs had the unusual ability to hydrolyze GTP to both GDP and GMP. More recently, we have begun to appreciate their novel structure, one that suggests unique mechanisms of GTP binding and hydrolysis and unique forms of regulation. In addition, we have begun to unravel some of their functions and to separate these function into those functions that do and those that do not require GTPase activity.

15 July 2010 in Molecular Biology of the Cell
Verified
Journal Article
Open access
AMAngela F. Messmer-Blust
Angela F. Messmer-Blust
SBSujata Balasubramanian
Sujata Balasubramanian
VGVictoria Y. Gorbacheva
Victoria Y. Gorbacheva
JJJonathan A. Jeyaratnam
Jonathan A. Jeyaratnam
Deborah J. VestalDeborah J. Vestal
Deborah J. Vestal
Exposure of cells to certain cytokines can alter how these same cells respond to later cues from other agents, such as extracellular matrix or growth factors. Interferon (IFN)-γ pre-exposure inhibits the spreading of fibroblasts on fibronectin. Expression of the IFN-γ–induced GTPase murine guanylate-binding protein-2 (mGBP-2) can phenocopy this inhibition and small interfering RNA knockdown of mGBP-2 prevents IFN-γ–mediated inhibition of cell spreading. Either IFN-γ treatment or mGBP-2 expression inhibits Rac activation during cell spreading. Rac is required for cell spreading. mGBP-2 also inhibits the activation of Akt during cell spreading on fibronectin. mGBP-2 is incorporated into a protein complex containing the catalytic subunit of phosphatidylinositol 3-kinase (PI3-K), p110. The association of mGBP-2 with p110 seems important for the inhibition of cell spreading because S52N mGBP-2, which does not incorporate into the protein complex with p110, is unable to inhibit cell spreading. PI3-K activation during cell spreading on fibronectin was inhibited in the presence of mGBP-2. Both IFN-γ and mGBP-2 also inhibit cell spreading initiated by platelet-derived growth factor treatment, which is also accompanied by inhibition of Rac activation by mGBP-2. This is the first report of a novel mechanism by which IFN-γ can alter how cells respond to subsequent extracellular signals, by the induction of mGBP-2.

1 June 2011 in Journal of Biological Chemistry
Verified
Journal Article
Open access
SBSujata Balasubramanian
Sujata Balasubramanian
MFMeiyun Fan
Meiyun Fan
AMAngela F. Messmer-Blust
Angela F. Messmer-Blust
CYChuan H. Yang
Chuan H. Yang
JTJill A. Trendel
Jill A. Trendel
Deborah J. VestalDeborah J. Vestal
Deborah J. Vestal
Matrix metalloproteinase-9 (MMP-9) is important in numerous normal and pathological processes, including the angiogenic switch during tumor development and tumor metastasis. Whereas TNF-α and other cytokines up-regulate MMP-9 expression, interferons (IFNs) inhibit MMP-9 expression. We found that IFN-γ treatment or forced expression of the IFN-induced GTPase, mGBP-2, inhibit TNF-α-induced MMP-9 expression in NIH 3T3 fibroblasts, by inhibiting MMP-9 transcription. The NF-κB transcription factor is required for full induction of MMP-9 by TNF-α. Both IFN-γ and mGBP-2 inhibit the transcription of a NF-κB-dependent reporter construct, suggesting that mGBP-2 inhibits MMP-9 induction via inhibition of NF-κB-mediated transcription. Interestingly, mGBP-2 does not inhibit TNF-α-induced degradation of IκBα or p65/RelA translocation into the nucleus. However, mGBP-2 inhibits p65 binding to a κB oligonucleotide probe in gel shift assays and to the MMP-9 promoter in chromatin immunoprecipitation assays. In addition, TNF-α activation of NF-κB in NIH 3T3 cells is dependent on Rac activation, as evidenced by the inhibition of TNF-α induction of NF-κB-mediated transcription by a dominant inhibitory form of Rac1. A role for Rac in the inhibitory action of mGBP-2 on NF-κB is further shown by the findings that mGBP-2 inhibits TNF-α activation of endogenous Rac and constitutively activate Rac can restore NF-κB transcription in the presence of mGBP-2. This is a novel mechanism by which IFNs can inhibit the cytokine induction of MMP-9 expression.

1 September 2016 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
ATAaron R. Tipton
Aaron R. Tipton
GNGeoffrey O. Nyabuto
Geoffrey O. Nyabuto
JTJill A. Trendel
Jill A. Trendel
TMTravis M. Mazur
Travis M. Mazur
JWJohn P. Wilson
John P. Wilson
Deborah J. VestalDeborah J. Vestal
Deborah J. Vestal

4 June 2022 in Cancers
Verified
Journal Article
Open access
PDF file
EHErin N. Hunt
Erin N. Hunt
JKJonathan P. Kopacz
Jonathan P. Kopacz
Deborah J. VestalDeborah J. Vestal
Deborah J. Vestal
At least one member of the Guanylate-Binding Protein (GBP) family of large interferon-induced GTPases has been classified as both a marker of good prognosis and as a potential drug target to treat breast cancers. However, the activity of individual GBPs appears to not just be tumor cell type–specific but dependent on the growth factor and/or cytokine environment in which the tumor cells reside. To clarify what we do and do not know about GBPs in breast cancer, the current literature on GBP-1, GBP-2, and GBP-5 in breast cancer has been assembled. In addition, we have analyzed the role of each of these GBPs in predicting recurrence-free survival (RFS), overall survival (OS), and distance metastasis-free survival (DMFS) as single gene products in different subtypes of breast cancers. When a large cohort of breast cancers of all types and stages were examined, GBP-1 correlated with poor RFS. However, it was the only GBP to do so. When smaller cohorts of breast cancer subtypes grouped into ER+, ER+/HER2−, and HER2+ tumors were analyzed, none of the GBPs influenced RFS, OS, or DMSF as single agents. The exception is GBP-5, which correlated with improved RFS in HER2+ breast cancers. All three GBPs individually predicted improved RFS, OS, and DMSF in ER− breast cancers, regardless of the PR or HER2 status, and TNBCs.